Pharmahungary Pharmahungary is a global provider of innovative PRECLINICAL AND CLINICAL R&D SERVICES, and offers novel technologies for co-development/outlicensing. Since 2003 Pharmahungary Group demonstrated capabilities to accomplish preclinical and clinical studies with excellent records of client satisfaction regarding quality, timelines, and budgets in over 200 development projects. Unique risk sharing opportunities are also available. LARGE ANIMAL models especially for cardiovascular and metabolic indications including Medical Devices. New: ISO 9001:2015 certified “Innovative preclinical and clinical R&D services and valorization of internal R&D projects”. Expertise of Pharmahungary Group: 1: PRECLINICAL services from cells to large animals, focusing on but not limited to CARDIOVASCULAR and METABOLIC PLATFORMS (myocardial infarction, stroke, heart failure, arrhythmias, diabetes, insulin resistance, hyperlipidemia, atherosclerosis, uremia, obesity) including co-morbidity and large animal models. Pharmahungary offers flexible services custom tailored to your projects and interim results. 2: CLINICAL RESEARCH SERVICES, focusing on clinical trials with medical devices, Investigator Initiated Trials, and studies with sensitive patient population that need strong scientific and regulatory support, including biologics, combination products and advanced therapeutics (ATMPs). 3: INTERNAL R&D PROJECTS to develop new diagnostics and therapeutics. Currently three early-stage patented technologies are open for out-licensing/co-development for ischemia-related diseases: - Biglycan therapy (biologics).  - MMP inhibitors (small molecules). - ProtectomiR (microRNAs).    Four novel supporting technology platforms are open for out-licensing/co-development: - Infarnosys (In Vitro Diagnostic system) - Hiddentox (combined in vitro, in vivo test system) - Vezics (chromatography platform for high-quality exosome isolation) - miRNAtarget (bioinformatics project for target prediction)